Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: Results from a follow-up study

British Journal of Cancer

Volumn 110, Issue 2, 2014, Pages 530-534

  Phelan, C M ^a   Iqbal, J ^b   Lynch, H T ^c   Lubinski, J ^d   Gronwald, J ^d   Moller, P ^e   Ghadirian, P ^f   Foulkes, W D ^g   Armel, S ^h   Eisen, A ⁱ   Neuhausen, S L ^j   Senter, L ^k   Singer, C F ^l   Ainsworth, P ^m   Kim Sing, C ⁿ   Tung, N ^o   Llacuachaqui, M ^b   Chornokur, G ^a   Ping, S ^b   Narod, S A ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d POMERANIAN MEDICAL UNIVERSITY   (Poland)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^j Beckmann Research Institute   (United States)

^k THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^l UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^m LONDON REGIONAL CANCER PROGRAM   (Canada)

ⁿ BRITISH COLUMBIA CANCER AGENCY   (Canada)

^o BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

BRCA1; BRCA2; colorectal cancer; prospective study

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; COLON CANCER; COLORECTAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; POPULATION RISK; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX RATIO; STANDARDIZED INCIDENCE RATIO; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BRCA2 PROTEIN; CANADA; COLORECTAL NEOPLASMS; EUROPE; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; INCIDENCE; MIDDLE AGED; RISK; UNITED STATES;

EID: 84892913739     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.741     Document Type: Article

References (20)

1. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72: 1117-1130.
2. Bermejo JL, Pérez AG, Hemminki K (2004) Contribution of the Defective BRCA1, BRCA2 and CHEK2 genes to the familial aggregation of breast cancer: a simulation study based on the Swedish Family-Cancer Database. Hered Cancer Clin Prac 2: 185-191.
3. Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310-1316.
4. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer Risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372.
5. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (eds) (2007) Cancer Incidence in Five Continents Vol. IXIARC Scientific Publications No. 160: Lyon, IARC.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (Internet). Lyon, France: International Agency for Research on Cancer; Available from http://globocan.iarc.fr.
7. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. The Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689.
8. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2012) SEER Cancer Statistics Review, 1975-2010. National Cancer Institute: Bethesda, MD, USA http://seer.cancer.gov/csr/1975- 2010/(based on November 2012 SEER data submission, posted to the SEER web site, 2013).
9. Jakubowska A, Scott R, Menkiszak J, Gronwald J, Byrski T, Huzarski T, Górski B, Cybulski C, Debniak T, Kowalska E, Starzyńska T, ?awniczak M, Narod S, Lubinski J (2003) A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet 11: 955-958.
10. King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302: 643-646.
11. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96: 15-21.
12. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer Incidence in Five Continents Vol. VIIIIARC Scientific Publications No. 155: Lyon, IARC.
13. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL, Fan I, Wong B, Narod SA (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68: 700-710.
14. Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB (2001) The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 10: 467-473.
15. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408.
16. Suchy J, Cybulski C, Górski B, Huzarski T, Byrski T, D?ebniak T, Gronwald J, Jakubowska A, Woko"orczyk D, Kurzawski G, K"adny J, Jawień A, Banaszkiewicz Z, Wiśniowski R, Wandzel P, Starzewski J, Lorenc Z, Korobowicz E, Krokowicz P, Horbacka K, Lubiński J, Narod SA (2010) BRCA1 mutations and colorectal cancer in Poland Poland study. Fam Cancer 9: 541-544.
17. Thompson D, Easton D. Breast Cancer Linkage Consortium (2001) Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 68: 410-419.
18. Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94: 1358-1365.
19. U.S. Preventive Services Task Force (2008) Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149: 627-637.
20. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792.